EA202092864A1 - Фармацевтическая композиция для парентерального капельного введения - Google Patents
Фармацевтическая композиция для парентерального капельного введенияInfo
- Publication number
- EA202092864A1 EA202092864A1 EA202092864A EA202092864A EA202092864A1 EA 202092864 A1 EA202092864 A1 EA 202092864A1 EA 202092864 A EA202092864 A EA 202092864A EA 202092864 A EA202092864 A EA 202092864A EA 202092864 A1 EA202092864 A1 EA 202092864A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- pharmaceutical composition
- parenteral
- acid
- asparaginate
- drop injection
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000002347 injection Methods 0.000 title 1
- 239000007924 injection Substances 0.000 title 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 2
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 abstract 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 abstract 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 abstract 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 abstract 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 abstract 1
- VWWQXMAJTJZDQX-UHFFFAOYSA-N Flavine adenine dinucleotide Natural products C1=NC2=C(N)N=CN=C2N1C(C(O)C1O)OC1COP(O)(=O)OP(O)(=O)OCC(O)C(O)C(O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UHFFFAOYSA-N 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 108010024636 Glutathione Proteins 0.000 abstract 1
- 229930010555 Inosine Natural products 0.000 abstract 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 abstract 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 abstract 1
- XJLXINKUBYWONI-NNYOXOHSSA-N NADP zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 229960005070 ascorbic acid Drugs 0.000 abstract 1
- 235000010323 ascorbic acid Nutrition 0.000 abstract 1
- 239000011668 ascorbic acid Substances 0.000 abstract 1
- 235000008207 calcium folinate Nutrition 0.000 abstract 1
- 239000011687 calcium folinate Substances 0.000 abstract 1
- -1 calcium folinate pentahydrate Chemical class 0.000 abstract 1
- 229940114136 calcium gluconate 500 mg Drugs 0.000 abstract 1
- 235000000639 cyanocobalamin Nutrition 0.000 abstract 1
- 239000011666 cyanocobalamin Substances 0.000 abstract 1
- 229960002104 cyanocobalamin Drugs 0.000 abstract 1
- 239000008121 dextrose Substances 0.000 abstract 1
- 108700003601 dimethylglycine Proteins 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 229960000304 folic acid Drugs 0.000 abstract 1
- 235000019152 folic acid Nutrition 0.000 abstract 1
- 239000011724 folic acid Substances 0.000 abstract 1
- 229960003180 glutathione Drugs 0.000 abstract 1
- 229960003786 inosine Drugs 0.000 abstract 1
- 229960000259 magnesium asparaginate Drugs 0.000 abstract 1
- ZHYLJCKTXNWNPJ-CEOVSRFSSA-L magnesium;(2s)-2,4-diamino-4-oxobutanoate Chemical compound [Mg+2].[O-]C(=O)[C@@H](N)CC(N)=O.[O-]C(=O)[C@@H](N)CC(N)=O ZHYLJCKTXNWNPJ-CEOVSRFSSA-L 0.000 abstract 1
- 235000007672 methylcobalamin Nutrition 0.000 abstract 1
- 239000011585 methylcobalamin Substances 0.000 abstract 1
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 abstract 1
- 229940078490 n,n-dimethylglycine Drugs 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 229960003193 potassium asparaginate Drugs 0.000 abstract 1
- NRFNNNBFDIFBLS-DKWTVANSSA-M potassium;(2s)-2,4-diamino-4-oxobutanoate Chemical compound [K+].[O-]C(=O)[C@@H](N)CC(N)=O NRFNNNBFDIFBLS-DKWTVANSSA-M 0.000 abstract 1
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 abstract 1
- 229940046664 taurine 500 mg Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Изобретение относится к области фармацевтической промышленности, а именно к фармацевтической композиции для парентерального капельного введения для применения при перенапряжении в условиях интенсивных нагрузок, характеризующейся тем, что содержит комплекс активных веществ при следующем соотношении компонентов: флавинадениндинуклеотид натрия - 40 мг; никотинамидадениндинуклеотидфосфат - 500 мг; фолиевая кислота - 15 мг; кальция фолинат пентагидрат - 50 мг; цианокобаламин - 1 мг; метилкобаламин - 500 мкг; глутатион - 600-1200 мг; -липоевая (тиоктовая) кислота - 50 мг; -D-фруктозо-1,6-дифосфат - 5000-10000 мг; N,N-диметилглицин - 300 мг; аскорбиновая кислота - 2000 мг; L-таурин - 500 мг; L-карнитин - 1000 мг; инозин - 400 мг; магния аспарагинат - 280 мг; калия аспарагинат - 320 мг; кальция глюконат - 500 мг; декстроза 5% - до 500 мл. Изобретение обеспечивает создание высокоэффективной лекарственной формы, которая может быть использована при различных состояниях, связанных с физическими перегрузками и перенапряжением отдельных органов и систем.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2019143808A RU2723950C1 (ru) | 2019-12-25 | 2019-12-25 | Фармацевтическая композиция для парентерального капельного введения |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202092864A1 true EA202092864A1 (ru) | 2021-06-30 |
Family
ID=71096163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202092864A EA202092864A1 (ru) | 2019-12-25 | 2020-12-23 | Фармацевтическая композиция для парентерального капельного введения |
Country Status (2)
| Country | Link |
|---|---|
| EA (1) | EA202092864A1 (ru) |
| RU (1) | RU2723950C1 (ru) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2747890C1 (ru) * | 2021-03-24 | 2021-05-17 | Общество С Ограниченной Ответственностью "Ива Фарм" | Средство для снижения риска и облегчения симптомов заражения бета-коронавирусной инфекцией |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019099731A1 (en) * | 2017-11-15 | 2019-05-23 | Activate Bio Physics Corp. | Formulations and dosage forms for enhancing performance or recovery from stress |
| RU2707948C1 (ru) * | 2019-09-02 | 2019-12-02 | Виктор Александрович Сисев | Фармацевтическая композиция для парентерального капельного введения (варианты) |
| RU2709500C1 (ru) * | 2019-10-15 | 2019-12-18 | Виктор Александрович Сисев | Фармацевтическая композиция для парентерального капельного введения |
-
2019
- 2019-12-25 RU RU2019143808A patent/RU2723950C1/ru active
-
2020
- 2020-12-23 EA EA202092864A patent/EA202092864A1/ru unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2723950C1 (ru) | 2020-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180007T1 (hr) | Formulacija koja sadrži gemcitabin-predlijek | |
| ES2191754T3 (es) | Fenil-dihidrobenzofuranos. | |
| HRP20210010T1 (hr) | Injekcijske farmaceutske formulacije lefamulina | |
| MX2019011620A (es) | Dosis y regimen para un inhibidor de la interaccion de hdm2-p53 en tumores hematologicos. | |
| PH12020550956A1 (en) | Sgc stimulators | |
| WO2018089328A8 (en) | TREATMENT OF CNS DISEASES USING GCS STIMULATORS | |
| MX2021005967A (es) | Formas purificadas de rofecoxib, métodos de fabricación y uso. | |
| EA202092864A1 (ru) | Фармацевтическая композиция для парентерального капельного введения | |
| DE59610031D1 (de) | Cyclohexyldihydrobenzofurane | |
| AR111464A1 (es) | Terapia combinada para el tratamiento de infecciones virales | |
| HRP20230300T1 (hr) | Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije | |
| MX2017005163A (es) | Composiciones de liberación prolongada de onapristona y métodos. | |
| EA201591653A1 (ru) | Композиции для лечения глазных расстройств с применением дипиридамола | |
| AR117626A1 (es) | COMPOSICIÓN QUE COMPRENDE INHIBIDOR DE LA a-1 PROTEINASA ALTAMENTE CONCENTRADO Y PROCEDIMIENTO PARA LA OBTENCIÓN DE LA MISMA | |
| EA201891860A1 (ru) | Фармацевтическая композиция пролонгированного высвобождения, содержащая цистеамин или его соли | |
| MX2018007377A (es) | Composicion de acido hialuronico para inyecciones en el pene. | |
| AR038632A1 (es) | Composicion farmaceutica | |
| EA201890929A1 (ru) | Низкие дозировки композиций дипиридамола для перорального приема и их использование | |
| PT1259229E (pt) | Utilizacao de benzotieno-[2,3-d]-pirimidinas com uma accao inibidora da pde v no tratamento do disfuncao erectil | |
| AR108792A1 (es) | Composiciones que comprenden timolol | |
| UA140727U (uk) | Фармацевтична композиція у формі капсул для лікування нейропатій | |
| RU2015105452A (ru) | Препарат для лечения костных наростов, головных болей и болей в сердце | |
| MXPA06000760A (es) | Composicion farmaceutica estable de carisoprodol y meloxicam. | |
| MX2016006375A (es) | Una combinacion de unidades de dosificacion para su uso en el tratamiento del parto prematuro. | |
| RU2008140019A (ru) | Способ лечения и профилактики эндометритов у коров |